GROW-H – CJC-1295 (No DAC) + Ipamorelin – 5 mg / 5 mg
GROW-H – CJC-1295 (No DAC) + Ipamorelin – 5 mg / 5 mg
GROW-H pairs CJC-1295 (No DAC) and Ipamorelin (5 mg each) — a GHRH analog plus a GHRP — the classic “amplify from two receptors” stack.
In healthy adults, CJC-1295 produced sustained increases in GH (2- to 10-fold) and IGF-1 (1.5- to 3-fold) lasting days per dose[1].
Ipamorelin adds a selective GH pulse without the cortisol spike of older secretagogues[2], so the two together drive a larger, cleaner release than either alone.
Supplied as a lyophilized powder for reconstitution. Figures above summarize published clinical (CJC-1295) and preclinical (Ipamorelin) research on these molecules and are provided as scientific reference for laboratory research only.
Couldn't load pickup availability
Need reconstitution solution? Don’t forget to add Bacteriostatic Water — available as a quick add in your cart before checkout.
Dual GH Secretagogue Blend
Two Pathways, One Goal: Synergistic Growth Hormone Research
This blend combines CJC-1295 (No DAC) and Ipamorelin — two peptides that stimulate growth hormone release through distinct but complementary mechanisms. CJC-1295 acts on GHRH receptors while Ipamorelin targets the ghrelin/GHS receptor. Together, they produce synergistic effects that exceed either peptide alone, making this blend essential for comprehensive GH axis research.
- 10mg total: CJC-1295 (5mg) + Ipamorelin (5mg)
- Dual-pathway GH stimulation (GHRH + Ghrelin receptors)
- Synergistic effects when combined
- Preserves natural pulsatile GH secretion patterns
- No DAC formulation for controlled research protocols
Complementary Mechanisms
How Two Peptides Amplify Growth Hormone Release
CJC-1295 stimulates GH release by binding to GHRH receptors on the pituitary — the same pathway used by the body's natural growth hormone-releasing hormone. Ipamorelin works through a completely different mechanism: it's a potent agonist of the ghrelin/GHS receptor, one of the most selective GH secretagogues known. This dual-receptor approach raises both baseline GH levels and peak secretion while maintaining natural pulsatile patterns.
- CJC-1295: GHRH receptor agonist (pituitary stimulation)
- Ipamorelin: Ghrelin/GHS receptor agonist (highly selective)
- Raises baseline GH levels (Ipamorelin effect)
- Produces higher peaks and troughs (CJC-1295 effect)
- Maintains natural pulsatile secretion pattern
Research Applications
From Bone Health to Metabolic Function — Comprehensive GH Research
The CJC-1295/Ipamorelin combination enables research across the full spectrum of GH-mediated effects. Ipamorelin alone has demonstrated benefits for bone health, muscle development, insulin release, and gastric function in animal models. Combined with CJC-1295's ability to normalize growth in GHRH-deficient models, this blend provides a comprehensive platform for GH axis research.
- Bone health and mineral density research
- Muscle repair and development studies
- Insulin secretion and metabolic function
- Bowel motility and gastric function research
- Body composition and lean mass studies
- GH axis dysfunction and restoration modeling
The Science Behind Dual-Pathway GH Stimulation: Why This Combination Works
The CJC-1295/Ipamorelin blend represents a strategic approach to growth hormone research — combining two peptides that work through completely different receptor systems to produce synergistic effects. This dual-pathway design achieves what neither peptide can accomplish alone.
CJC-1295 (No DAC) is a modified GHRH analog that stimulates the pituitary's growth hormone-releasing hormone receptors. Research demonstrates it normalizes growth in GHRH knockout models and preserves natural pulsatile GH secretion even during continuous stimulation. The "No DAC" formulation (without Drug Affinity Complex) provides shorter-acting effects ideal for controlled research protocols.
Ipamorelin is among the most selective GH secretagogues ever developed — a potent ghrelin/GHS receptor agonist with minimal effects on cortisol, prolactin, or other hormones. Studies have shown it improves bone mineral content, counteracts glucocorticoid-induced bone loss, stimulates pancreatic insulin release, and enhances gastric motility in postoperative ileus models.
When combined, these peptides create a "higher set point" for GH secretion. Ipamorelin raises baseline levels such that CJC-1295 produces both higher peaks and higher troughs — all while maintaining the natural ebb and flow of pulsatile secretion. For research teams investigating GH axis function, bone metabolism, body composition, or metabolic regulation, this blend provides enhanced effects without substantially increased complexity.
For research use only. Not for human consumption.
Scientific Literature
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2005;91(3):799-805.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.
Packaged with care, shipped fast.
The Qovigen Difference
GROW-H – CJC-1295 (No DAC) + Ipamorelin – 5 mg / 5 mg — Qovigen vs. a typical supplier.
Qovigen
GROW-H – CJC-1295 (No DAC) + Ipamorelin – 5 mg / 5 mg
Qovigen Peptides
Competitor
GROW-H – CJC-1295 (No DAC) + Ipamorelin – 5 mg / 5 mg
Typical Competitor
01 /
Higher Purity
02 /
Better Price
03 /
Faster Shipping
04 /
Verified Quality
After testing more than $8,500 worth of vials over the past year, Qovigen ranks first — set apart by genuinely new production technology.
Dr Aimen Arij
Doctor of Pharmacology · Lead Writer, dosagepeptide.com